Chandrasekar Baskaran
Department of Cardiology, Chest Diseases Hospital, PO Box 4082, Safat, 13041, Kuwait.
Indian Heart J. 2025 Jan-Feb;77(1):48-50. doi: 10.1016/j.ihj.2025.01.004. Epub 2025 Jan 24.
Industry's influence on clinical trials is well known and extends to various aspects beyond funding, including industry-affiliated authors and industry-affiliated analysts. An area of potential concern is presentation of analyzed data that does not appear favorable to the desired study outcome. Such important data are at times not accorded prominence in discussion. The present article analyses such concerns in data presentation in the landmark trials of two cardiac devices the use of which has increased markedly in recent years (DanGer Shock trial and COAPT trial). It is seen that important data that did not appear favorable to the intended study outcome were relegated mostly to Supplement Section, where they are likely to receive less attention, with little discussion allocated in the text.
业界对临床试验的影响是众所周知的，并且其影响范围超出了资金领域，涉及包括业界附属作者和业界附属分析师在内的各个方面。一个潜在令人担忧的领域是呈现出的分析数据似乎不利于预期的研究结果。这类重要数据有时在讨论中未得到突出体现。本文分析了近年来使用量显著增加的两种心脏设备的里程碑式试验（DanGer Shock试验和COAPT试验）中数据呈现方面的此类问题。可以看到，那些看似不利于预期研究结果的重要数据大多被归入补充部分，在那里它们可能较少受到关注，正文中也几乎没有对其进行讨论。
